KCLEAGENICS MEDICAL is an equal bridge between scientific discovery, clinical expertise and patient care — translating the latest oncology research into better outcomes for people living with cancer.
Understanding which cancers affect the most people guides where research effort is most urgently needed. Our trial portfolio is shaped by this epidemiological reality.
Source: American Cancer Society, 2024
Source: GLOBOCAN / WHO, 2022
From early-phase trials to translational insights, KCLG Medical operates at every stage of the clinical evidence pipeline — ensuring findings reach the patients and clinicians who need them.
We design and conduct Phase I–III trials across oncology, haematology, and metabolic medicine, with pre-specified endpoints and independent oversight.
Our systematic reviews and meta-analyses distil the best available evidence, informing clinical guidelines and shaping prescribing practice across the NHS and beyond.
We collaborate with NHS Trusts, academic institutions, and industry sponsors — providing site management, investigator support, and regulatory expertise.
Our research agenda is shaped by unmet clinical need — focusing on areas where new evidence can meaningfully change patient outcomes today, not in a decade.
Join a Trial →CLL, SLL, AML and lymphoma — exploring novel agents, drug combinations and supportive care strategies.
Biomarker-driven trial design and molecular profiling to match patients with the therapies most likely to benefit them.
Checkpoint inhibitors, CAR-T adjacent therapies and immunotherapy combination regimens across solid tumours.
Investigating the relationship between metabolic health, obesity-related risk, and cancer susceptibility across diverse populations.
A snapshot of recent regulatory approvals and research advances reshaping oncology care — and informing how we design and prioritise future trials.
The FDA approved nivolumab in combination with chemotherapy as a first-line treatment for adult and adolescent patients with previously untreated, advanced classical Hodgkin lymphoma — widening options for haematology patients.
Source: FDA Oncology Approvals, 2026
A new PROTAC (proteolysis-targeting chimera) therapy received its first oncology approval — a milestone for precision medicine that opens a new mechanistic class for genomically-driven trial design.
Source: FDA Oncology Approvals, 2026
An all-oral treatment combination was approved for older adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy — a major step for accessibility and quality of life.
Source: FDA Oncology Approvals, 2026
The first immunotherapy combination in over three decades was approved for high-risk non-muscle-invasive bladder cancer, offering a bladder-sparing option for patients who don't respond to standard therapy.
Source: FDA Oncology Approvals, 2026
A landmark review of where oncology research is heading — exploring emerging therapies, earlier detection strategies, and what the evidence now says about improving survival outcomes in one of the most challenging cancers.
Explore Our Insights →Source: YouTube · Pancreatic Cancer Research
Evidence-based commentary, trial updates, and clinical briefings for healthcare professionals and informed patients.
A review of the mechanistic rationale and early clinical data supporting statin co-administration in ibrutinib-treated CLL patients.
A plain-language guide covering informed consent, safety monitoring, your rights as a participant, and what happens at each study visit.
An explanation of how pre-specified statistical analysis plans prevent selective reporting and protect the integrity of trial findings.
"Every day that a proven therapy sits in a journal instead of a clinic, a patient who could have benefited doesn't. Our work exists to close that gap — rigorously, ethically, and urgently."— KCLG Medical Research Team
Learn how to discuss clinical trial participation with your consultant, what eligibility criteria mean, and how to access our active studies.
We work with NHS consultants and GPs to identify eligible patients and support site initiation for our ongoing and upcoming trials.
From academic collaborations to industry-sponsored trials, we offer flexible partnership models with full regulatory and operational support.
